{"disease":{"id":"borderline-ovarian-serous-tumor","name":"borderline ovarian serous tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02101788","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00551070","title":"Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}